GLPwatch

Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes.

Cell Rep · 2021

Last updated 2026-05-28

Researchers studied how two GLP-1 drugs, semaglutide and taspoglutide, interact with a receptor in the body called GLP-1R, which helps control blood sugar and appetite. Using advanced imaging, they found that both drugs bind to the receptor in similar ways but cause different movements within the receptor and the drugs themselves, which may explain why they have different effects or side effects.

AI summary of the abstract below.

JournalCell Rep, 2021
Citations47
Relative citation ratio2.88
NIH percentile83
Molecules semaglutide
Conditions studied Type 2 Diabetes, Obesity

Abstract

The glucagon-like peptide-1 receptor (GLP-1R) regulates insulin secretion, carbohydrate metabolism, and appetite and is an important target for treatment of type 2 diabetes and obesity. Multiple GLP-1R agonists have entered into clinical trials, with some, such as semaglutide, progressing to approval. Others, including taspoglutide, failed due to the high incidence of side effects or insufficient efficacy. GLP-1R agonists have a broad spectrum of signaling profiles, but molecular understanding is limited by a lack of structural information on how different agonists engage with the GLP-1R. Here, we report cryoelectron microscopy (cryo-EM) structures and cryo-EM 3D variability analysis of semaglutide- and taspoglutide-bound GLP-1R-Gs protein complexes. These reveal similar peptide interactions to GLP-1 but different motions within the receptor and bound peptides, providing insights into the molecular determinants of GLP-1R peptide engagement.

Verbatim abstract via PubMed 34260945 ↗

Related research